Calidi Biotherapeutics Operating Cash Flow Growth & History (CLDI)
Calidi Biotherapeutics's operating cash flow was −$21.3M for fiscal 2025.
View full Calidi Biotherapeutics company overviewCalidi Biotherapeutics annual operating cash flow history
| Fiscal year | Period ended | Operating cash flow | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$21.3M | −$1.6M | — |
| 2024 | 2024-12-31 | −$19.7M | $7.3M | — |
| 2023 | 2023-12-31 | −$27.0M | −$13.8M | — |
| 2022 | 2022-12-31 | −$13.2M | −$12.1M | — |
| 2021 | 2021-12-31 | −$1.1M | — | — |
Calidi Biotherapeutics quarterly operating cash flow
| Fiscal quarter | Period ended | Operating cash flow | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$4.4M | $527,000 | — |
| Q1 2026 | 2026-03-31 | −$4.1M | $3.0M | — |
| Q4 2025 | 2025-12-31 | −$5.0M | $379,000 | — |
| Q3 2025 | 2025-09-30 | −$4.2M | $708,000 | — |
| Q2 2025 | 2025-06-30 | −$4.9M | $614,000 | — |
| Q1 2025 | 2025-03-31 | −$7.1M | −$3.3M | — |
| Q4 2024 | 2024-12-31 | −$5.4M | −$237,000 | — |
| Q3 2024 | 2024-09-30 | −$4.9M | $8.6M | — |
| Q2 2024 | 2024-06-30 | −$5.5M | −$321,000 | — |
| Q1 2024 | 2024-03-31 | −$3.8M | −$724,000 | — |
| Q4 2023 | 2023-12-31 | −$5.2M | −$1.3M | — |
| Q3 2023 | 2023-09-30 | −$13.5M | −$4.9M | — |
| Q2 2023 | 2023-06-30 | −$5.2M | −$4.9M | — |
| Q1 2023 | 2023-03-31 | −$3.1M | −$2.6M | — |
| Q4 2022 | 2022-12-31 | −$3.9M | — | — |
| Q3 2022 | 2022-09-30 | −$8.6M | −$7.1M | — |
| Q2 2022 | 2022-06-30 | −$268,679 | −$149,875 | — |
| Q1 2022 | 2022-03-31 | −$465,131 | — | — |
| Q3 2021 | 2021-09-30 | −$1.5M | — | — |
| Q2 2021 | 2021-06-30 | −$118,804 | — | — |
Calidi Biotherapeutics operating cash flow trends
Between the periods ended 2021-12-31 and 2025-12-31, Calidi Biotherapeutics's operating cash flow decreased from −$1.1M to −$21.3M, a change of −$20.2M. The latest reported quarter, Q2 2026, shows −$4.4M.
What operating cash flow means
Operating cash flow is the cash generated or used by a company’s core operations. It incorporates working-capital movements and other operating cash items, and it is the starting point for calculating free cash flow.
SEC-reported operating cash flow
TickerStat standardizes net cash provided by or used in operating activities reported in company SEC filings. It is historical filing data before capital expenditures, financing activities, and investing activities. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Calidi Biotherapeutics source filings ↗